On January 31, Newland Pharmaceutical welcomed a delegation from Nanjing Sino Drug, led by Chairman Dr. Li Xinping, for a visit and business exchange. The delegation toured Newland's R&D center, quality control center, and manufacturing facilities, gaining a closer look at its R&D capabilities, production capacity, and operations.

The two sides exchanged views on key challenges in innovative drug development and commercialization. Discussions covered technology collaboration, joint platform development, and the advancement of R&D projects toward commercialization, with both sides exploring opportunities for deeper collaboration.

Nanjing Sinuo New Drug Research and Development Co., Ltd.

Nanjing Sino Drug is an innovative radiopharmaceutical company based in Nanjing. The company focuses on developing targeted radiopharmaceuticals for cancer diagnosis and treatment, with a theranostic approach that enables the same drug conjugate to be used for both imaging and therapy by switching the radioisotope.

Sino Drug is supported by its Cytostar® single-cell antibody discovery platform and high-throughput targeted peptide screening platform, together with more than 20 years of radiopharmaceutical development experience within its founding team. Leveraging its expertise and industry resources, the company is developing an integrated radiopharmaceutical R&D platform designed to accelerate drug development, reduce development risks, and advance precision oncology.